Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King

The annual incidence of pancreatic cancer is nearly 50,000 patients. The 5-year overall survival is only 9%, and there remains a great need for better therapy. A subset of these patients presents with locally advanced disease. Multidisciplinary therapy has evolved to include some combination of systemic chemotherapy, locoregional radiation, and surgery in select patients with excellent biology. This review will address the thoughtful evidence-based and individualized approach to these patients.

Automated summary

The annual incidence of pancreatic cancer is nearly 50,000 patients, with a 5-year overall survival rate of only 9%. Multidisciplinary therapy, including systemic chemotherapy, locoregional radiation, and surgery, is evolving to provide individualized and evidence-based treatment for patients with locally advanced disease.